Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Screening protocol for the identification of modulators by immunofluorescent cell-based assay.

Klett J, Gómez-Casero E, Méndez-Pertuz M, Urbano-Cuadrado M, Megias D, Blasco MA, Martínez S, Pastor J, Blanco-Aparicio C.

Chem Biol Drug Des. 2019 Aug 30. doi: 10.1111/cbdd.13616. [Epub ahead of print]

PMID:
31469231
2.

Multiple cancer pathways regulate telomere protection.

Bejarano L, Bosso G, Louzame J, Serrano R, Gómez-Casero E, Martínez-Torrecuadrada J, Martínez S, Blanco-Aparicio C, Pastor J, Blasco MA.

EMBO Mol Med. 2019 Jul;11(7):e10292. doi: 10.15252/emmm.201910292. Epub 2019 Jun 13.

3.

Multiple cancer pathways regulate telomere protection.

Bejarano L, Bosso G, Louzame J, Serrano R, Gómez-Casero E, Martínez-Torrecuadrada J, Martínez S, Blanco-Aparicio C, Pastor J, Blasco MA.

EMBO Mol Med. 2019 Jun 13. pii: e10292. doi: 10.15252/emmm.201910292. [Epub ahead of print]

4.

Discovery of novel triazolo[4,3-b]pyridazin-3-yl-quinoline derivatives as PIM inhibitors.

Martínez-González S, Rodríguez-Arístegui S, Gómez de la Oliva CA, Hernández AI, González Cantalapiedra E, Varela C, García AB, Rabal O, Oyarzabal J, Bischoff JR, Klett J, Albarrán MI, Cebriá A, Ajenjo N, García-Serelde B, Gómez-Casero E, Cuadrado-Urbano M, Cebrián D, Blanco-Aparicio C, Pastor J.

Eur J Med Chem. 2019 Apr 15;168:87-109. doi: 10.1016/j.ejmech.2019.02.022. Epub 2019 Feb 19.

PMID:
30802730
5.

Lysosomal trapping of palbociclib and its functional implications.

Llanos S, Megias D, Blanco-Aparicio C, Hernández-Encinas E, Rovira M, Pietrocola F, Serrano M.

Oncogene. 2019 May;38(20):3886-3902. doi: 10.1038/s41388-019-0695-8. Epub 2019 Jan 28.

PMID:
30692638
6.

Author Correction: STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis.

Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, Doglio L, Martínez L, Martínez-Saez E, Ramón Y Cajal S, Megías D, Hernández-Encinas E, Blanco-Aparicio C, Martínez L, Zarzuela E, Muñoz J, Fustero-Torre C, Piñeiro-Yáñez E, Hernández-Laín A, Bertero L, Poli V, Sanchez-Martinez M, Menendez JA, Soffietti R, Bosch-Barrera J, Valiente M.

Nat Med. 2018 Sep;24(9):1481. doi: 10.1038/s41591-018-0108-5.

PMID:
29921958
7.

STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis.

Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, Doglio L, Martínez L, Martínez-Saez E, Ramón Y Cajal S, Megías D, Hernández-Encinas E, Blanco-Aparicio C, Martínez L, Zarzuela E, Muñoz J, Fustero-Torre C, Piñeiro-Yáñez E, Hernández-Laín A, Bertero L, Poli V, Sanchez-Martinez M, Menendez JA, Soffietti R, Bosch-Barrera J, Valiente M.

Nat Med. 2018 Jul;24(7):1024-1035. doi: 10.1038/s41591-018-0044-4. Epub 2018 Jun 11. Erratum in: Nat Med. 2018 Jun 19;:.

PMID:
29892069
8.

Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies.

Toledo RA, Garralda E, Mitsi M, Pons T, Monsech J, Vega E, Otero Á, Albarran MI, Baños N, Durán Y, Bonilla V, Sarno F, Camacho-Artacho M, Sanchez-Perez T, Perea S, Álvarez R, De Martino A, Lietha D, Blanco-Aparicio C, Cubillo A, Domínguez O, Martínez-Torrecuadrada JL, Hidalgo M.

Clin Cancer Res. 2018 Aug 1;24(15):3550-3559. doi: 10.1158/1078-0432.CCR-18-0103. Epub 2018 Mar 27.

9.

Inhibition of TRF1 Telomere Protein Impairs Tumor Initiation and Progression in Glioblastoma Mouse Models and Patient-Derived Xenografts.

Bejarano L, Schuhmacher AJ, Méndez M, Megías D, Blanco-Aparicio C, Martínez S, Pastor J, Squatrito M, Blasco MA.

Cancer Cell. 2017 Nov 13;32(5):590-607.e4. doi: 10.1016/j.ccell.2017.10.006.

10.

Modulation of telomere protection by the PI3K/AKT pathway.

Méndez-Pertuz M, Martínez P, Blanco-Aparicio C, Gómez-Casero E, Belen García A, Martínez-Torrecuadrada J, Palafox M, Cortés J, Serra V, Pastor J, Blasco MA.

Nat Commun. 2017 Nov 2;8(1):1278. doi: 10.1038/s41467-017-01329-2.

11.

Identification of novel PI3K inhibitors through a scaffold hopping strategy.

Martínez González S, Hernández AI, Álvarez RM, Rodríguez A, Ramos-Lima F, Bischoff JR, Albarrán MI, Cebriá A, Hernández-Encinas E, García-Arocha J, Cebrián D, Blanco-Aparicio C, Pastor J.

Bioorg Med Chem Lett. 2017 Nov 1;27(21):4794-4799. doi: 10.1016/j.bmcl.2017.09.059. Epub 2017 Sep 30.

PMID:
29017786
12.

Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus.

Jiménez-García MP, Lucena-Cacace A, Robles-Frías MJ, Ferrer I, Narlik-Grassow M, Blanco-Aparicio C, Carnero A.

Oncotarget. 2017 Jul 22;8(35):58872-58886. doi: 10.18632/oncotarget.19438. eCollection 2017 Aug 29.

13.

The role of PIM1/PIM2 kinases in tumors of the male reproductive system.

Jiménez-García MP, Lucena-Cacace A, Robles-Frías MJ, Narlik-Grassow M, Blanco-Aparicio C, Carnero A.

Sci Rep. 2016 Nov 30;6:38079. doi: 10.1038/srep38079.

14.

Tissue damage and senescence provide critical signals for cellular reprogramming in vivo.

Mosteiro L, Pantoja C, Alcazar N, Marión RM, Chondronasiou D, Rovira M, Fernandez-Marcos PJ, Muñoz-Martin M, Blanco-Aparicio C, Pastor J, Gómez-López G, De Martino A, Blasco MA, Abad M, Serrano M.

Science. 2016 Nov 25;354(6315). pii: aaf4445.

PMID:
27884981
15.

ETP-46321, a dual p110α/δ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis.

Aragoneses-Fenoll L, Montes-Casado M, Ojeda G, Acosta YY, Herranz J, Martínez S, Blanco-Aparicio C, Criado G, Pastor J, Dianzani U, Portolés P, Rojo JM.

Biochem Pharmacol. 2016 Apr 15;106:56-69. doi: 10.1016/j.bcp.2016.02.005. Epub 2016 Feb 13.

16.

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.

Goodson WH 3rd, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami GN, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lyerly HK, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP Sr, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart ME, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson PA, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom SE, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z.

Carcinogenesis. 2015 Jun;36 Suppl 1:S254-96. doi: 10.1093/carcin/bgv039. Review. Erratum in: Carcinogenesis. 2016 Mar;37(3):344.

17.

Disruptive chemicals, senescence and immortality.

Carnero A, Blanco-Aparicio C, Kondoh H, Lleonart ME, Martinez-Leal JF, Mondello C, Scovassi AI, Bisson WH, Amedei A, Roy R, Woodrick J, Colacci A, Vaccari M, Raju J, Al-Mulla F, Al-Temaimi R, Salem HK, Memeo L, Forte S, Singh N, Hamid RA, Ryan EP, Brown DG, Wise JP Sr, Wise SS, Yasaei H.

Carcinogenesis. 2015 Jun;36 Suppl 1:S19-37. doi: 10.1093/carcin/bgv029. Review.

18.

Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage.

García-Beccaria M, Martínez P, Méndez-Pertuz M, Martínez S, Blanco-Aparicio C, Cañamero M, Mulero F, Ambrogio C, Flores JM, Megias D, Barbacid M, Pastor J, Blasco MA.

EMBO Mol Med. 2015 Jul;7(7):930-49. doi: 10.15252/emmm.201404497.

19.

A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes.

Hill R, Kalathur RK, Callejas S, Colaço L, Brandão R, Serelde B, Cebriá A, Blanco-Aparicio C, Pastor J, Futschik M, Dopazo A, Link W.

Breast Cancer Res. 2014 Dec 9;16(6):482. doi: 10.1186/s13058-014-0482-y.

20.

PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.

Martín-Sánchez E, Odqvist L, Rodríguez-Pinilla SM, Sánchez-Beato M, Roncador G, Domínguez-González B, Blanco-Aparicio C, García Collazo AM, Cantalapiedra EG, Fernández JP, Curiel del Olmo S, Pisonero H, Madureira R, Almaraz C, Mollejo M, Alves FJ, Menárguez J, González-Palacios F, Rodríguez-Peralto JL, Ortiz-Romero PL, Real FX, García JF, Bischoff JR, Piris MA.

PLoS One. 2014 Nov 11;9(11):e112148. doi: 10.1371/journal.pone.0112148. eCollection 2014.

21.

Non-genotoxic activation of p53 through the RPL11-dependent ribosomal stress pathway.

Morgado-Palacin L, Llanos S, Urbano-Cuadrado M, Blanco-Aparicio C, Megias D, Pastor J, Serrano M.

Carcinogenesis. 2014 Dec;35(12):2822-30. doi: 10.1093/carcin/bgu220. Epub 2014 Oct 24.

PMID:
25344835
22.

Genetic Modeling of PIM Proteins in Cancer: Proviral Tagging and Cooperation with Oncogenes, Tumor Suppressor Genes, and Carcinogens.

Aguirre E, Renner O, Narlik-Grassow M, Blanco-Aparicio C.

Front Oncol. 2014 May 15;4:109. doi: 10.3389/fonc.2014.00109. eCollection 2014. Review.

23.

Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis.

Moneo V, Serelde BG, Blanco-Aparicio C, Diaz-Uriarte R, Avilés P, Santamaría G, Tercero JC, Cuevas C, Carnero A.

BMC Cancer. 2014 Apr 23;14:281. doi: 10.1186/1471-2407-14-281.

24.

The PIM family of serine/threonine kinases in cancer.

Narlik-Grassow M, Blanco-Aparicio C, Carnero A.

Med Res Rev. 2014 Jan;34(1):136-59. doi: 10.1002/med.21284. Epub 2013 Apr 10. Review.

PMID:
23576269
25.

Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia.

Narlik-Grassow M, Blanco-Aparicio C, Cecilia Y, Perez M, Muñoz-Galvan S, Cañamero M, Renner O, Carnero A.

PLoS One. 2013;8(4):e60277. doi: 10.1371/journal.pone.0060277. Epub 2013 Apr 2. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/1b8b6002-4e0f-4c5d-8ae8-fd45447b6149. Renner, Oliver [added].

26.

Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.

Blanco-Aparicio C, Carnero A.

Biochem Pharmacol. 2013 Mar 1;85(5):629-643. doi: 10.1016/j.bcp.2012.09.018. Epub 2012 Oct 5. Review.

PMID:
23041228
27.

Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.

Martínez González S, Hernández AI, Varela C, Lorenzo M, Ramos-Lima F, Cendón E, Cebrián D, Aguirre E, Gomez-Casero E, Albarrán MI, Alfonso P, García-Serelde B, Mateos G, Oyarzabal J, Rabal O, Mulero F, Gonzalez-Granda T, Link W, Fominaya J, Barbacid M, Bischoff JR, Pizcueta P, Blanco-Aparicio C, Pastor J.

Bioorg Med Chem Lett. 2012 Aug 15;22(16):5208-14. doi: 10.1016/j.bmcl.2012.06.093. Epub 2012 Jul 4.

PMID:
22819764
28.

Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas.

Martín-Sánchez E, Rodríguez-Pinilla SM, Sánchez-Beato M, Lombardía L, Domínguez-González B, Romero D, Odqvist L, García-Sanz P, Wozniak MB, Kurz G, Blanco-Aparicio C, Mollejo M, Alves FJ, Menárguez J, González-Palacios F, Rodríguez-Peralto JL, Ortiz-Romero PL, García JF, Bischoff JR, Piris MA.

Haematologica. 2013 Jan;98(1):57-64. doi: 10.3324/haematol.2012.068510. Epub 2012 Jul 16.

29.

The essential role of PIM kinases in sarcoma growth and bone invasion.

Narlik-Grassow M, Blanco-Aparicio C, Cecilia Y, Peregrina S, Garcia-Serelde B, Muñoz-Galvan S, Cañamero M, Carnero A.

Carcinogenesis. 2012 Aug;33(8):1479-86. doi: 10.1093/carcin/bgs176. Epub 2012 May 22.

30.

p38α limits the contribution of MAP17 to cancer progression in breast tumors.

Guijarro MV, Vergel M, Marin JJ, Muñoz-Galván S, Ferrer I, Ramon y Cajal S, Roncador G, Blanco-Aparicio C, Carnero A.

Oncogene. 2012 Oct 11;31(41):4447-59. doi: 10.1038/onc.2011.619. Epub 2012 Jan 23.

PMID:
22266858
31.

Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.

Pastor J, Oyarzabal J, Saluste G, Alvarez RM, Rivero V, Ramos F, Cendón E, Blanco-Aparicio C, Ajenjo N, Cebriá A, Albarrán MI, Cebrián D, Corrionero A, Fominaya J, Montoya G, Mazzorana M.

Bioorg Med Chem Lett. 2012 Feb 15;22(4):1591-7. doi: 10.1016/j.bmcl.2011.12.130. Epub 2012 Jan 5.

PMID:
22266039
32.

PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.

Gómez-Abad C, Pisonero H, Blanco-Aparicio C, Roncador G, González-Menchén A, Martinez-Climent JA, Mata E, Rodríguez ME, Muñoz-González G, Sánchez-Beato M, Leal JF, Bischoff JR, Piris MA.

Blood. 2011 Nov 17;118(20):5517-27. doi: 10.1182/blood-2011-03-344374. Epub 2011 Sep 21.

33.

Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation.

Ferrer I, Blanco-Aparicio C, Peregrina S, Cañamero M, Fominaya J, Cecilia Y, Lleonart M, Hernandez-Losa J, Ramon y Cajal S, Carnero A.

Cell Cycle. 2011 Aug 15;10(16):2751-62. Epub 2011 Aug 15.

34.

Spinophilin loss contributes to tumorigenesis in vivo.

Ferrer I, Peregrino S, Cañamero M, Cecilia Y, Blanco-Aparicio C, Carnero A.

Cell Cycle. 2011 Jun 15;10(12):1948-55. Epub 2011 Jun 15.

PMID:
21670604
35.

Down-regulation of spinophilin in lung tumours contributes to tumourigenesis.

Molina-Pinelo S, Ferrer I, Blanco-Aparicio C, Peregrino S, Pastor MD, Alvarez-Vega J, Suarez R, Verge M, Marin JJ, Hernandez-Losa J, Ramon y Cajal S, Paz-Ares L, Carnero A.

J Pathol. 2011 Sep;225(1):73-82. doi: 10.1002/path.2905. Epub 2011 May 19.

PMID:
21598252
36.

Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.

Blanco-Aparicio C, Collazo AM, Oyarzabal J, Leal JF, Albarán MI, Lima FR, Pequeño B, Ajenjo N, Becerra M, Alfonso P, Reymundo MI, Palacios I, Mateos G, Quiñones H, Corrionero A, Carnero A, Pevarello P, Lopez AR, Fominaya J, Pastor J, Bischoff JR.

Cancer Lett. 2011 Jan 28;300(2):145-53. doi: 10.1016/j.canlet.2010.09.016. Epub 2010 Nov 3.

PMID:
21051136
37.

Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.

Blanco-Aparicio C, Cañamero M, Cecilia Y, Pequeño B, Renner O, Ferrer I, Carnero A.

PLoS One. 2010 Feb 19;5(2):e9305. doi: 10.1371/journal.pone.0009305.

38.

Inhibiting PI3K as a therapeutic strategy against cancer.

Paz-Ares L, Blanco-Aparicio C, García-Carbonero R, Carnero A.

Clin Transl Oncol. 2009 Sep;11(9):572-9. Review.

PMID:
19775996
39.

Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.

Renner O, Blanco-Aparicio C, Grassow M, Cañamero M, Leal JF, Carnero A.

Cancer Res. 2008 Dec 1;68(23):9643-53. doi: 10.1158/0008-5472.CAN-08-1539.

40.

Genetic modelling of the PTEN/AKT pathway in cancer research.

Renner O, Blanco-Aparicio C, Carnero A.

Clin Transl Oncol. 2008 Oct;10(10):618-27. Review.

PMID:
18940742
41.

S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis.

Leal JF, Ferrer I, Blanco-Aparicio C, Hernández-Losa J, Ramón Y Cajal S, Carnero A, Lleonart ME.

Carcinogenesis. 2008 Nov;29(11):2089-95. doi: 10.1093/carcin/bgn198. Epub 2008 Aug 19.

PMID:
18713839
42.

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF.

Curr Cancer Drug Targets. 2008 May;8(3):187-98. Review.

PMID:
18473732
43.

Cellular senescence bypass screen identifies new putative tumor suppressor genes.

Leal JF, Fominaya J, Cascón A, Guijarro MV, Blanco-Aparicio C, Lleonart M, Castro ME, Ramon Y Cajal S, Robledo M, Beach DH, Carnero A.

Oncogene. 2008 Mar 27;27(14):1961-70. Epub 2007 Oct 29.

PMID:
17968325
44.

MAP17 enhances the malignant behavior of tumor cells through ROS increase.

Guijarro MV, Leal JF, Blanco-Aparicio C, Alonso S, Fominaya J, Lleonart M, Castellvi J, Ramon y Cajal S, Carnero A.

Carcinogenesis. 2007 Oct;28(10):2096-104. Epub 2007 Jun 4.

PMID:
17548903
45.

Levels of p27(kip1) determine Aplidin sensitivity.

Moneo V, Serelde BG, Leal JF, Blanco-Aparicio C, Diaz-Uriarte R, Aracil M, Tercero JC, Jimeno J, Carnero A.

Mol Cancer Ther. 2007 Apr;6(4):1310-6.

46.

MAP17 overexpression is a common characteristic of carcinomas.

Guijarro MV, Leal JF, Fominaya J, Blanco-Aparicio C, Alonso S, Lleonart M, Castellvi J, Ruiz L, Ramon Y Cajal S, Carnero A.

Carcinogenesis. 2007 Aug;28(8):1646-52. Epub 2007 Apr 9.

PMID:
17426052
47.

Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.

Renner O, Fominaya J, Alonso S, Blanco-Aparicio C, Leal JF, Carnero A.

Carcinogenesis. 2007 Jul;28(7):1418-25. Epub 2007 Mar 19.

PMID:
17372272
48.

PTEN, more than the AKT pathway.

Blanco-Aparicio C, Renner O, Leal JF, Carnero A.

Carcinogenesis. 2007 Jul;28(7):1379-86. Epub 2007 Mar 6. Review.

PMID:
17341655
49.

Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer.

Blanco-Aparicio C, Pérez-Gallego L, Pequeño B, Leal JF, Renner O, Carnero A.

Carcinogenesis. 2007 Mar;28(3):584-94. Epub 2006 Oct 17.

PMID:
17050554
50.

Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.

Moneo V, Serelde BG, Fominaya J, Leal JF, Blanco-Aparicio C, Romero L, Sánchez-Beato M, Cigudosa JC, Tercero JC, Piris MA, Jimeno J, Carnero A.

J Cell Biochem. 2007 Feb 1;100(2):339-48.

PMID:
16888811

Supplemental Content

Loading ...
Support Center